BioInsights raises $2.7M to bring AI to functional medicine
What's the deal? BioInsightsDealroom has a profile for this one. Try Dealroom →, a Tampa-area startup building software for functional medicine practices, has raised $2.7 million in a seed round, according to a Form D filing with the Securities and Exchange Commission on September 22. Seven investors backed the offering, which began with an initial sale on September 13. The company declined to name backers or discuss its valuation.
What's the endgame? BioInsights, based in Lutz, Florida, and incorporated in Delaware in 2026, sells an "all-in-one clinical operating system" to practitioners who treat patients through diet, supplements, and lifestyle changes rather than conventional drugs. Its core product, the Predictive Dysfunction Index, uses a probability model to match patient biomarkers against a library of more than 300 treatment protocols.
The platform also bundles intake forms, lab ordering across 100-plus test panels, e-prescribing, telehealth, and supplement fulfillment. The company claims it saves providers more than 790 hours a year and generates clinical notes in 90 seconds, though no independent audit backs those figures.
Who's behind it? Chief executive officer Travis Bond, an MD with an MBA, previously founded Tampa chronic-care company CareSync and led digital neurodiagnostics firm Altoida. Co-founder Erin Coletti is a physician the company says has logged over 40,000 patient encounters. Dennis Mihale is chief medical officer, with Maximilian Bügler leading technology.
What could go wrong? The corner of healthcare IT BioInsights is entering is already crowded. Specialised electronic health records such as Practice Better, CerboDealroom has a profile for this one. Try Dealroom →, OptiMantraDealroom has a profile for this one. Try Dealroom →, and Power2PracticeDealroom has a profile for this one. Try Dealroom → have staked out the integrative health space, several offering protocol libraries and lab integrations of their own.
BioInsights also cites an "$82 billion market" in its materials, drawn from a broad wellness segment that stretches well beyond functional medicine. More conservative estimates place the US complementary and alternative medicine market between $41 billion and $45 billion in 2024.
Why now? The startup is scaling. It is hiring a director of clinical product at a base salary starting at $135,000 for a hybrid role in Lutz, with the listing emphasising ownership of AI-driven clinical decision support.
The signal: At $2.7 million, the round sits in the lower tier of seed deals by size, a modest bet on automating a niche of alternative healthcare. Whether practitioners embrace point-of-care AI — or find it intrusive — will decide if BioInsights can carve space in an already contested market.
Read more: founderland.ai
Image credit: BioInsights
